|Bid||4,720.00 x 6100|
|Ask||4,920.00 x 13000|
|Day's Range||4,756.00 - 4,820.50|
|52 Week Range||4,260.00 - 5,520.00|
|PE Ratio (TTM)||20.20|
|Forward Dividend & Yield||2.02 (4.16%)|
|1y Target Est||N/A|
In January, GlaxoSmithKline's (GSK.L) new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. Miels - a long-time protege of AstraZeneca (AZN.L) CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis (NOVN.S) and Merck & Co (MRK.N) in producing multibillion-dollar blockbusters, so Walmsley has prioritised plans to refocus both its research and marketing efforts in a drive for fewer but bigger new drugs.
Amgen would be better off stringing together small deals, rather than attempting a megamerger, an analyst suggested Monday.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
By Brian Marckx, CFA NASDAQ:CEMI Chembio (NASDAQ:CEMI) reported Q4 2017 financial results and provided a business update. Despite declining on a sequential basis, both product sales and total revenue ...
AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 28.2x, which is lower than the industry average of 32.9x. Although some investors may jump to the conclusion that thisRead More...
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Key data on whether an AstraZeneca drug improves overall survival for those with non-small cell lung cancer that has spread elsewhere in the body will not now be released until the second half of the year, ...
AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live with and without the company’s treatment.
LONDON (Reuters) - AstraZeneca (AZN.L) now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase ...
AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase III trial, known as Mystic, ...
While the U.S. stock markets appear overheated, savvy investors can find more value in the international markets, particularly Europe, where stocks remain cheap. We asked five top advisors and MoneyShow.com contributors to highlight favorite stocks. They came back with seven picks.
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
NEW YORK/TOKYO, March 8 (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses. The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck's immunotherapy Keytruda, could be worth up to $5.76 billion to Eisai, but most of that would be contingent on eventual sales.
The Zacks Analyst Blog Highlights: United States Steel, Allegheny, Century, Astrazeneca and Ferrari
In December 2017, AstraZeneca PLC (LSE:AZN) released its most recent earnings update. Generally, analyst forecasts appear to be pessimistic, as a -27.11% fall in profits is expected in the upcomingRead More...
Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world. Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs - something Roche (ROG.S) aims to leverage, for example, with last month's $2 billion (1.46 billion pounds) purchase of Flatiron Health. Real-world evidence involves collecting data outside traditional randomised clinical trials, the current gold standard for judging medicines, and interest in the field is ballooning.
Investors are spinning Viela Bio out of the biologics arm of AstraZeneca PLC and providing the new drug developer with up to $250 million in financing.
MedImmune Inc., the research and development arm of global drug giant AstraZeneca PLC, is spinning out a new company named Viela Bio with plans to create 100 jobs within the next three to five years. As part of the launch, Viela Bio said it raised $250 million from a consortium of investors led by 6 Dimensions Capital, Boyu Capital and Hillhouse Capital with additional funds from Temasek and Sirona Capital. AstraZeneca (AZN) will remain the largest minority shareholder of Viela Bio, which will lease space on MedImmune's campus in Gaithersburg.
AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases. The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest example of the British drugmaker pruning its non-core drug development work to focus on priority areas, notably in cancer. Chief Executive Pascal Soriot said earlier this month that AstraZeneca had a drug pipeline that was "over-sized relative to the current size of our company".